This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.
It’s an approach that has already yielded one FDA- and EMA-approved product – Amgen’s Imlygic (talimogene laherparepvec) – which was launched in 2015 for melanoma but hasn’t made much
Oncolytic virus-based therapies are consistent with and complement that strategy.”. The first oncolytic virus therapy to reach western markets was Amgen’s Imlygic (talimogene laherparepvec or T-Vec) which was
The first and so far only therapy of this type to reach the market is Amgen’s melanoma therapy Imlygic (talimogene laherparepvec or T-Vec, approved by the FDA in 2015,
Amgen’s Imlygic (talimogene laherparepvec) has been approved in Europe and the US since 2015 for use in melanoma that has recurred after surgery, but sales have been small.
This form of immuno-oncology has been spearheaded by Amgen, whose Imlygic (talimogene laherparepvec or T-Vec) was approved by the FDA last year, although it was not the first oncolytic
Imlygic (talimogene laherparepvec) was turned down by NICE in earlier guidance, with the agency arguing that it could not justify its use because of uncertainty about the therapy's effects on
More from news
Approximately 4 fully matching, plus 19 partially matching documents found.
Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and kills cancer cells, and to date a handful of therapies – Amgen’s Imlygic (talimogene laherparepvec) in the US and
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...